313927--2/27/2008--CHURCH_&_DWIGHT_CO_INC_/DE/

related topics
{product, market, service}
{customer, product, revenue}
{product, liability, claim}
{operation, international, foreign}
{cost, regulation, environmental}
{debt, indebtedness, cash}
{operation, natural, condition}
{acquisition, growth, future}
{property, intellectual, protect}
{product, candidate, development}
{regulation, government, change}
If the reputation of one or more of our leading brands erodes significantly, it could have a material impact on our financial results. We have recently developed and commenced sales of a number of new products and line extensions, but if they do not gain widespread customer acceptance or if they cause sales of our existing products to decline, our financial performance could decline. We may discontinue products or product lines which could result in returns, asset write-offs and shutdown costs. We also may engage in product recalls that would reduce our cash flow and earnings. We face intense competition in a mature industry and we may be required to increase expenditures and accept lower profit margins to preserve or maintain our market share. Unless the markets in which we compete grow substantially, a loss of market share will result in reduced sales levels and declining operating results. Providing price concessions or trade terms that are acceptable to our trade customers, or the failure to do so, could adversely affect our sales and profitability. Reductions in inventory by our trade customers, including as a result of consolidations in the retail industry, could adversely affect sales in periods during which the reduction results in reduced orders for our products. A continued shift in the retail market from food and drug stores to club stores and mass merchandisers could cause our sales to decline. Loss of any of our principal customers could significantly decrease our sales and profitability. Our substantial indebtedness could adversely affect our financial condition and ability to operate our businesses and repay the indebtedness. Our substantial indebtedness could adversely affect our financial condition and ability to operate our businesses and repay the indebtedness. We may make acquisitions that result in dilution to our current stockholders or increase our indebtedness, or both. In addition, acquisitions that are not properly integrated or are otherwise unsuccessful could strain or divert our resources. Our condom product line could suffer if the spermicide N-9 is proved or perceived to be harmful. The Company s manufacturing and other facilities may be subject to disruption from events beyond the Company s control. Price increases in raw and packaging materials or energy costs could erode our profit margins, which could harm operating results. We are subject to various government regulations in the countries in which we operate that could adversely affect our business. We are subject to risks related to our international operations that could adversely affect our results of operations. We are subject to risks related to our international operations that could adversely affect our results of operations. Environmental matters create potential liability risks. Product liability claims could adversely affect the Company s sales and operating results. Failure to maximize or successfully assert intellectual property rights could materially adversely affect our competitiveness.

Full 10-K form ▸

related documents
313927--2/24/2009--CHURCH_&_DWIGHT_CO_INC_/DE/
313927--2/24/2010--CHURCH_&_DWIGHT_CO_INC_/DE/
313927--2/26/2007--CHURCH_&_DWIGHT_CO_INC_/DE/
353569--2/26/2010--QUIDEL_CORP_/DE/
225263--3/11/2008--NEWPORT_CORP
8146--4/9/2010--ASTRO_MED_INC_/NEW/
1270597--3/31/2006--MERISANT_CO
868368--12/11/2009--ROCHESTER_MEDICAL_CORPORATION
276889--12/14/2007--QUANEX_CORP
1270597--3/23/2007--MERISANT_CO
868368--12/10/2010--ROCHESTER_MEDICAL_CORPORATION
18937--2/26/2008--CERADYNE_INC
70793--12/11/2006--NBTY_INC
70793--11/27/2007--NBTY_INC
225263--3/16/2006--NEWPORT_CORP
1014507--6/1/2006--SCHICK_TECHNOLOGIES_INC
943894--3/28/2008--EZENIA_INC
1423221--12/18/2009--Quanex_Building_Products_CORP
849502--2/27/2008--RAMTRON_INTERNATIONAL_CORP
736822--7/24/2008--IMMUCOR_INC
1060822--2/28/2007--CARTERS_INC
1029506--11/29/2010--RALCORP_HOLDINGS_INC_/MO
70793--12/1/2008--NBTY_INC
868368--12/26/2006--ROCHESTER_MEDICAL_CORPORATION
790818--3/18/2010--X_RITE_INC
941604--2/27/2006--COINSTAR_INC
868368--12/4/2007--ROCHESTER_MEDICAL_CORPORATION
1013606--2/29/2008--ENDOLOGIX_INC_/DE/
70793--11/30/2009--NBTY_INC
1423221--12/20/2010--Quanex_Building_Products_CORP